ATE439853T1 - Zusammensetzung zur behandlung von ichthyosis unter verwendung von antitrypsin - Google Patents

Zusammensetzung zur behandlung von ichthyosis unter verwendung von antitrypsin

Info

Publication number
ATE439853T1
ATE439853T1 AT03777001T AT03777001T ATE439853T1 AT E439853 T1 ATE439853 T1 AT E439853T1 AT 03777001 T AT03777001 T AT 03777001T AT 03777001 T AT03777001 T AT 03777001T AT E439853 T1 ATE439853 T1 AT E439853T1
Authority
AT
Austria
Prior art keywords
antitrypsin
composition
diluent
carrier
protease inhibitor
Prior art date
Application number
AT03777001T
Other languages
English (en)
Inventor
Ian C Bathurst
Philip A Pemberton
David J Sundin
James W Mayhew
Arturo J Angel
Philip J Barr
Original Assignee
Arriva Prometic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arriva Prometic Inc filed Critical Arriva Prometic Inc
Application granted granted Critical
Publication of ATE439853T1 publication Critical patent/ATE439853T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03777001T 2002-11-20 2003-11-20 Zusammensetzung zur behandlung von ichthyosis unter verwendung von antitrypsin ATE439853T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42770202P 2002-11-20 2002-11-20
PCT/GB2003/005049 WO2004045634A1 (en) 2002-11-20 2003-11-20 Composition and method for treating inflammatory diseases using protease inhibitors

Publications (1)

Publication Number Publication Date
ATE439853T1 true ATE439853T1 (de) 2009-09-15

Family

ID=32326583

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03777001T ATE439853T1 (de) 2002-11-20 2003-11-20 Zusammensetzung zur behandlung von ichthyosis unter verwendung von antitrypsin

Country Status (9)

Country Link
US (1) US20080095806A1 (de)
EP (1) EP1562621B1 (de)
JP (1) JP2006508971A (de)
AT (1) ATE439853T1 (de)
AU (1) AU2003286258B2 (de)
CA (1) CA2506839A1 (de)
DE (1) DE60328909D1 (de)
ES (1) ES2330516T3 (de)
WO (1) WO2004045634A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006510657A (ja) * 2002-12-06 2006-03-30 アライバ ファーマシューティカルズ，インコーポレイティド 中耳炎の処置のための方法および組成物
WO2004096113A2 (en) * 2003-04-28 2004-11-11 Medical Instill Technologies, Inc. Container with valve assembly for filling and dispensing substances, and apparatus and method for filling
US7217690B2 (en) 2003-10-07 2007-05-15 Kimberly-Clark Worldwide, Inc. Compositions of sunflower trypsin inhibitors
WO2005117955A1 (en) * 2004-05-19 2005-12-15 Arriva Pharmaceuticals, Inc. Treatment of atopic dermatitis with unglycosylated alpha one-antitrypsin
US7553810B2 (en) 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US7608579B2 (en) 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US7468350B2 (en) 2004-06-16 2008-12-23 Pneumrx, Inc. Glue composition for lung volume reduction
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
JP5113519B2 (ja) 2004-07-08 2013-01-09 ヌームアールエックス・インコーポレーテッド 胸膜滲出の治療装置，治療方法及び材料
JP2006176461A (ja) * 2004-12-24 2006-07-06 Dai Ichi Seiyaku Co Ltd 粒状物
GB0525680D0 (en) * 2005-12-16 2006-01-25 Peplin Ltd Therapeutic compositions
ES2377206T3 (es) * 2006-01-06 2012-03-23 Ed Geistlich Sohne Ag Fur Chemische Industrie Composiciones irradiadas y tratamiento de cánceres con radiación en combinación con taurolidina y/o taurultam
US9222728B2 (en) * 2006-04-24 2015-12-29 Medinstill Development Llc Penetrable and resealable lyophilization device
US20110130338A1 (en) 2008-01-21 2011-06-02 Dermadis Sa Use of serine protease inhibitors in the treatment of skin diseases
WO2009137827A2 (en) * 2008-05-09 2009-11-12 Tiara Pharmaceuticals, Inc. Controlled release of n-acetylcysteine (nac) for reduction of systemic and/or vascular inflammation
WO2010014306A1 (en) * 2008-07-28 2010-02-04 Tyco Healthcare Group Lp Antimicrobial and anticoagulant compositions and methods
ES2332645B1 (es) 2009-06-30 2010-10-18 Grifols, S.A. Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica.
WO2011056667A2 (en) * 2009-10-28 2011-05-12 Guthery Eugene B Rosacea topical skin treatment method and formulation
EP2611459B1 (de) * 2010-08-31 2019-12-11 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Alpha-1 Antitrypsin abgeleitete Polypeptide zur Verwendung in der Behandlung von Entzündung
US9518107B2 (en) 2010-08-31 2016-12-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Pharmaceutical compositions containing polypeptides derived from α-1 antitrypsin and methods of use thereof
EP3366301A1 (de) * 2012-05-14 2018-08-29 Teijin Limited Strahlungssterilisierungsbeständige proteinzusammensetzung
JP6105252B2 (ja) * 2012-10-26 2017-03-29 株式会社コーセー 皮膚内挙動評価方法
US9593339B1 (en) * 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11484515B2 (en) 2017-12-12 2022-11-01 University of Pittsburgh—of the Commonwealth System of Higher Education Thermoresponsive hydrogel containing polymer microparticles for controlled drug delivery to the ear
CN109223707B (zh) * 2018-09-13 2020-12-08 中国药科大学 一种尿酸酶外用凝胶制剂、其制备方法及用途
US12342819B2 (en) * 2019-08-23 2025-07-01 The Hong Kong University Of Science And Technology Elasnin, a bacteriostatic agent that has potent antibiofilm activities against both mono- and multi-species biofilm
US20240285571A1 (en) * 2020-10-01 2024-08-29 Microbion Corporation Methods of treating bone infections
CN113173970B (zh) * 2021-06-15 2022-11-15 北京林业大学 一种核桃粕抗炎肽fpl及其应用
EP4676515A1 (de) * 2023-03-09 2026-01-14 Merck Sharp & Dohme LLC Formulierungen mit actriia-polypeptidvarianten

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57145817A (en) * 1981-03-05 1982-09-09 Satoru Yamazaki Remedy for peptic ulcer
US4816449A (en) * 1984-08-09 1989-03-28 Immunetech Pharmaceuticals Immunotherapeutic anti-inflammatory peptide agents
US4680175A (en) * 1984-02-07 1987-07-14 Interferon Sciences, Inc. Interferon administration vehicles
US5026686A (en) * 1989-02-01 1991-06-25 Washington University Antiviral peptides
CS275231B2 (en) * 1989-09-29 1992-02-19 Ustav Makormolekularni Chemie Medicine bottle
CA2091354C (en) * 1990-10-16 2005-04-12 John Lezdey Treatment of inflammation
US5346886A (en) * 1993-11-15 1994-09-13 John Lezdey Topical α-1-antitrypsin, non-aqueous lipid miscible, benzalkonium chloride compositions for treating skin
GB2318732A (en) * 1996-11-01 1998-05-06 Johnson & Johnson Medical Wound healing compositions containing alpha-1-antitrypsin
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
IL138594A0 (en) * 1998-04-01 2001-10-31 Biotech Australia Pty Ltd Use of protease inhibitors for treating skin wounds
AUPP508798A0 (en) * 1998-08-05 1998-08-27 Biotech Australia Pty Limited Method of treating psoriasis
US6096327A (en) * 1998-11-05 2000-08-01 Protease Sciences Inc. Cosmetic compositions containing human type serine protease inhibitors for revitalizing the skin
AU1101501A (en) * 1999-10-27 2001-05-08 K-Quay Enterprises, Llc Methods and compositions for treatment of keratoconus using protease inhibitors
US6627785B1 (en) * 2000-02-29 2003-09-30 Virginia Commwealth University Wound dressings with protease-lowering activity

Also Published As

Publication number Publication date
EP1562621B1 (de) 2009-08-19
CA2506839A1 (en) 2004-06-03
US20080095806A1 (en) 2008-04-24
AU2003286258A1 (en) 2004-06-15
ES2330516T3 (es) 2009-12-11
JP2006508971A (ja) 2006-03-16
WO2004045634A1 (en) 2004-06-03
AU2003286258B2 (en) 2006-12-21
DE60328909D1 (de) 2009-10-01
EP1562621A1 (de) 2005-08-17

Similar Documents

Publication Publication Date Title
DE60328909D1 (de) Zusammensetzung zur behandlung von ichthyosis unter verwendung von antitrypsin
BR0312275A (pt) Composição e método para tratamento de superfìcies ou de ar, superfìcie assim tratada e artigo de manufatura
DE60311820D1 (de) Neue verwendung von pyrimidin- oder triazin-2-carbonsäurenitrilen zur behandlung von krankheiten, die mit cysteinproteaseaktivität assoziiert sind, und neue pyridimidin-2-carbonsäurenitrilderivate
NO20061736L (no) Krystallform av epotilon B
DE60117605D1 (de) Thiazolyl-inhibitoren von tyrosinkinasen der tec-familie
BR0317715A (pt) Composições e processos de uso de collajolie
GEP20063871B (en) Inhibitors of factor xa and other serine proteases involved in the coagulation cascade
DE50207442D1 (de) Behandlung der akne mit lipoxygenase inhibitoren
BR9812699A (pt) Derivados de benzamidina
FI972628A0 (fi) Uudet sulfonamidit
EA200501805A1 (ru) Фармацевтическая композиция, содержащая ингибитор фермента дипептидилпептидазы
DE60329316D1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
WO2003091259A8 (en) Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
DK0719154T3 (da) Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel
MX9800146A (es) Nuevos inhibidores de trombina, su preparacion y su uso.
SE9602263D0 (sv) New amino acid derivatives
FI103111B1 (fi) Menetelmä proteolyyttisen entsyymin inhibiittoreina käyttökelpoisten sakkariinijohdannaisten valmistamiseksi
ATE318606T1 (de) Zusammenstellungen zur prophylaxe und behandlung von allergien des typus i
MXPA05004384A (es) Piperacinil y diacepanil benzamidas y benztioamidas.
DE69814444D1 (de) Kombination von angiotensing-convertin-enzyme hemmern mit diuretikum zur behandlung von störungen der mikrozirkulation
ATE333451T1 (de) Verwendung von nitrilenverbindungen als arztneimittel
BR0212535A (pt) Compostos e composições como inibidores de catepsina
IS5966A (is) Nýjar amídínóafleiður og notkun þeirra sem þrombínhemlar
ATE443044T1 (de) Tace inhibitoren
YU49422B (sh) Upotreba inhibitora ugljenične anhidraze za proizvodnju medikamenata za tretiranje makularnog edema ili makularne degeneracije izazvane starošću

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties